Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Author:

Muffly Lori1,Pasquini Marcelo C.2,Martens Michael3,Brazauskas Ruta23,Zhu Xiaochun2,Adekola Kehinde4,Aljurf Mahmoud5,Ballen Karen K.6,Bajel Ashish7,Baron Frederic8,Battiwalla Minoo9,Beitinjaneh Amer10,Cahn Jean-Yves11,Carabasi Mathew12,Chen Yi-Bin13,Chhabra Saurabh14,Ciurea Stefan1516,Copelan Edward17,D’Souza Anita2,Edwards John18,Foran James19,Freytes Cesar O.20,Fung Henry C.21,Gale Robert Peter22,Giralt Sergio23,Hashmi Shahrukh K.2425,Hildebrandt Gerhard C.26,Ho Vincent27,Jakubowski Ann23,Lazarus Hillard28,Luskin Marlise R.29,Martino Rodrigo30,Maziarz Richard31,McCarthy Philip32,Nishihori Taiga33,Olin Rebecca34,Olsson Richard F.3536,Pawarode Attaphol37,Peres Edward38,Rezvani Andrew R.1,Rizzieri David39,Savani Bipin N.40,Schouten Harry C.41,Sabloff Mitchell42,Seftel Matthew43,Seo Sachiko44,Sorror Mohamed L.4546,Szer Jeff47,Wirk Baldeep M.48,Wood William A.49,Artz Andrew50

Affiliation:

1. Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA;

2. Center for International Blood and Marrow Transplant Research and

3. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI;

4. Northwestern Memorial Hospital, Chicago, IL;

5. Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia;

6. Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA;

7. Royal Melbourne Hospital, Victoria, VIC, Australia;

8. Centre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium;

9. Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD;

10. Department of Hematology and Oncology, University of Miami, Miami, FL;

11. Department of Hematology, University Hospital, Grenoble, France;

12. Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA;

13. Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA;

14. Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI;

15. Department of Stem Cell Transplantation and Cellular Therapy and

16. Transplant Myeloid Study Group, The University of Texas MD Anderson Cancer Center, Houston, TX;

17. Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC;

18. Indiana Blood and Marrow Transplantation, Indianapolis, IN;

19. Mayo Clinic, Jacksonville, FL;

20. Texas Transplant Institute, San Antonio, TX;

21. Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA;

22. Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom;

23. Memorial Sloan Kettering Cancer Center, New York, NY;

24. Department of Internal Medicine, Mayo Clinic, Minneapolis, MN;

25. Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia;

26. Department of Internal Medicine, University of Kentucky Chandler Medical Center, Lexington, KY;

27. Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA;

28. Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH;

29. Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA;

30. Divison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;

31. Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR;

32. Blood and Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY;

33. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

34. Department of Medicine, University of California San Francisco Medical Center, San Francisco, CA;

35. Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;

36. Center for Clinical Research Sormland, Uppsala University, Uppsala, Sweden;

37. Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI;

38. Bone Marrow Transplant Program, Henry Ford Hospital, Detroit, MI;

39. Division of Hematologic Malignancies and Cellular Therapy, Blood and Marrow Transplant Clinic, Duke University, Durham, NC;

40. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;

41. Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands;

42. Division of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada;

43. Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada;

44. National Cancer Research Center, East Hospital, Kashiwa, Chiba, Japan;

45. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

46. Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA;

47. Department Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, VIC, Australia;

48. Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA;

49. Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and

50. Section of Hematology/Oncology, University of Chicago School of Medicine, Chicago, IL

Abstract

Key Points Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies. Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3